The purpose of this study is to assess the potential interactions between intravenous
methamphetamine and oral selegiline.
To determine the safety of the selegiline concurrent with d-methamphetamine challenges of
15mg & 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v.
methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm
study design to evaluate the safety of selegiline treatment, compared to placebo treatment,
concurrent with i.v. methamphetamine challenges.
- Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence;
non-treatment seeking individuals
- Be able to verbalize understanding of consent form; provide written informed consent
- Please contact site for more information